MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter

Liu, Xin; Cheng, Feiran; Bai, Xue; Zhao, Tong; Zhao, Limin; Wang, Lei; Li, Mingqi; Wu, Xianxian; Chen, Xiaohui; Tang, Peixiao; Wang, Mengxue; Jiang, Leiming; Yan, Chaoqi; Pei, Fenghua; Gao, Xu; Ma, Ning; Yang, Baofeng; Zhang, Yong

doi:10.1016/j.isci.2022.104708

Cited by 3 publications

(5 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We respectively (Hur et al, 2017;Imaoka et al, 2016). Our previous research has shown that plasma miR-203 levels are modifiable in individuals with varying BMI, suggesting its utility as a plasma marker for the early prediction of obesity (Liu, Cheng, et al, 2022). In this study, et al, 2021).…”

Section: Knockdown Of Mir-203 Aggravated Mitochondrial Dysfunction Of...mentioning

confidence: 57%

“…MiR‐203 is a stable biomarker in blood circulation that has shown potential in identifying the progression of tumor and obesity (Hur et al., 2017 ; Imaoka et al., 2016 ; Liu, Cheng, et al., 2022 ). To further evaluate the diagnostic value of miR‐203 in the context of aging, particularly heart aging, we included a total of 60 subjects in this study.…”

Section: Resultsmentioning

confidence: 99%

“…have revealed the potential of plasma miR‐203 as a biomarker for predicting metastasis and poor prognosis in human colorectal and gastric cancer, respectively (Hur et al., 2017 ; Imaoka et al., 2016 ). Our previous research has shown that plasma miR‐203 levels are modifiable in individuals with varying BMI, suggesting its utility as a plasma marker for the early prediction of obesity (Liu, Cheng, et al., 2022 ). In this study, we assessed the association between aging, cardiac performance, and miR‐203 level in a general population sample without prevalent cardiovascular risk factors and structural heart disease.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, miR‐203 has been found to be involved in several cardiovascular diseases, including diabetic cardiomyopathy (DCM) (Yang et al., 2019 ), myocardial infarction (MI) (Wang et al., 2021 ) and myocardial ischemia–reperfusion (I/R) injury (Tan et al., 2020 ). Recently, our published studies suggested that miR‐203 plays a role in controlling obesity and dyslipidemia by inhibiting ASBT expression (Liu, Cheng, et al., 2022 ). These studies suggest that miR‐203 plays a critical role in regulating disease development, and may have potential as a gene therapy tool and a biomarker for disease prevention and treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine

Zhao,

Tang,

Lin

et al. 2023

Aging Cell

Self Cite

View full text Add to dashboard Cite

Heart aging is a prevalent cause of cardiovascular diseases among the elderly. NAD+ depletion is a hallmark feature of aging heart, however, the molecular mechanisms that affect NAD+ depletion remain unclear. In this study, we identified microRNA‐203 (miR‐203) as a senescence‐associated microRNA that regulates NAD+ homeostasis. We found that the blood miR‐203 level negatively correlated with human age and its expression significantly decreased in the hearts of aged mice and senescent cardiomyocytes. Transgenic mice with overexpressed miR‐203 (TgN (miR‐203)) showed resistance to aging‐induced cardiac diastolic dysfunction, cardiac remodeling, and myocardial senescence. At the cellular level, overexpression of miR‐203 significantly prevented D‐gal‐induced cardiomyocyte senescence and mitochondrial damage, while miR‐203 knockdown aggravated these effects. Mechanistically, miR‐203 inhibited PARP1 expression by targeting its 3′UTR, which helped to reduce NAD+ depletion and improve mitochondrial function and cell senescence. Overall, our study first identified miR‐203 as a genetic tool for anti‐heart aging by restoring NAD+ function in cardiomyocytes.

show abstract

Section: Knockdown Of Mir-203 Aggravated Mitochondrial Dysfunction Of...mentioning

confidence: 57%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine

Zhao,

Tang,

Lin

et al. 2023

Aging Cell

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recent studies also reveal that miRNAs are involved in adipogenesis and obesity [ 143 ], which are potential targets for obesity treatment. For example, miR-203 can target an apical sodium-dependent bile acid transporter to regulate bile acid homeostasis and decrease obesity and dyslipidemia [ 144 ]. In addition, the expression of circulating miRNAs such as miR-99-5p/100-5p can be regulated by lifestyle intervention, and is associated with a decrease in fat accumulation and an improvement in glucose metabolism in patients with abdominal obesity [ 145 ].…”

Section: Clinical Management Of Obesitymentioning

confidence: 99%

The Related Metabolic Diseases and Treatments of Obesity

2022

View full text Add to dashboard Cite

Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.

show abstract

The miR-203/ZBTB20/MAFA Axis Orchestrates Pancreatic β-Cell Maturation and Identity During Weaning and Diabetes

Li,

Yang,

Sun

et al. 2024

Diabetes

View full text Add to dashboard Cite

Maturation of postnatal β cells is regulated in a cell-autonomous manner, and metabolically stressed β cells regress to an immature state, ensuring defective β-cell function and the onset of type 2 diabetes. The molecular mechanisms connecting the nutritional transition to β-cell maturation remain largely unknown. Here, we report a miR-203/ZBTB20/MAFA regulatory axis that mediates the β-cell maturation process. We show that miR-203 level in β cells changes during the nutritional transition and that miR-203 inhibits β-cell maturation at the neonatal stage and under high-fat diet (HFD) conditions. Using single-cell RNA sequencing, we demonstrated that miR-203 elevation promoted the transition of immature β cells into CgBHi endocrine cells, while suppressing gene expressions associated with β-cell maturation in a ZBTB20/MAFA-dependent manner. ZBTB20 is an authentic target of miR-203 and transcriptionally upregulates MAFA expression. Manipulating the miR-203/ZBTB20/MAFA axis may therefore offer a novel strategy for boosting functional β-cell numbers to alleviate diabetes.

show abstract

MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter

Cited by 3 publications

References 64 publications

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine

The Related Metabolic Diseases and Treatments of Obesity

The miR-203/ZBTB20/MAFA Axis Orchestrates Pancreatic β-Cell Maturation and Identity During Weaning and Diabetes

Contact Info

Product

Resources

About

MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter

Cited by 3 publications

References 64 publications

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD+ axis in aging murine

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD+ axis in aging murine

The Related Metabolic Diseases and Treatments of Obesity

The miR-203/ZBTB20/MAFA Axis Orchestrates Pancreatic β-Cell Maturation and Identity During Weaning and Diabetes

Contact Info

Product

Resources

About

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine

MiR‐203 improves cardiac dysfunction by targeting PARP1‐NAD⁺ axis in aging murine